SUMMARY
immunoassays the apparent cross-reactlvlty of an endogenous digoxin-like immunoreactive substance or substances (DLIS) has been sporadically reported. 3 DLIS has been isolated from various body tissues,4 the blood of patients with renal failures and hepatic failure, 6 the serum of women in the third trimester of pregnancy/ from neonates 8 and from cord serum, 9 It is unknown whether DLIS has a physiological role as an endogenous inhibitor of Na+-K+ ATPase, although it has been proposed to have natriuretic properties 1o • 1J and to be a mediator in hypertension. 12 The current experimental data indicate that DLIS is of low molecular weight, transported in blood bound to plasma proteins, possibly a peptide but unrelated to the already elucidated atrial natriuretic factor. 13 .14 Despite many small clinical studies 'of the presence and proposed effects of DLIS in various patient subgroups, no study has compared patients who have various forms of organ dysfunction with control subjects. The primary objectives of this study are to document the incidence of DLIS in Intensive Care Vnit (ICV) patients and to determine if a relationship exists between DLIS and particular organ dysfunction in critically ill adults.
PATIENTS AND METHODS

Intensive Care Patients
DLIS was measured in one hundred and seventeen consecutive patients admitted to the ICV of the Royal Prince Alfred Hospital, between June and October 1987. Seventeen of these patients had received digitalis, spironolactone or corticosteroid therapy within two weeks prior to admission or during the study period and were excluded from the study. On the day of admission 10 ml of heparinised blood was drawn from each patient, centrifuged and stored at 4°C. The plasma was used for the determination of concentrations of digoxin, creatinine, urea, electrolytes, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), albumin and total bile salts. Blood was also collected for haematological analysis of haemoglobin, platelets, leucocytes, activated partial thromboplastin time (APTT) and prothrombin index (PI). On the same day a spot sample of urine was collected and analysed for sodium concentration, and the daily creatinine was determined from a 24-hour urine collection. Patients whose stay in ICV was anticipated to be at least 72 hours had serial daily plasma digoxin concentration measurements.
For the purpose of this study renal dysfunction was defined by the presence both of a plasma creatmme concentration > 150 )lmol/l and plasma urea concentration ~9.0 mmol/1.
Hepatic dysfunction was defined as either: (a) total bilirubin ~20 )lmolll and AST ~55 V/I or ALT ~55 V/I or GGT ~55 V/I; or (b) AST ~110 V/I or ALT ~110 V/I. Admission APACHE l5 score was calculated for each patient.
Control Group. Ten ml of heparinised blood was obtained from one hundred routine adult blood donors to the New South Wales Blood Bank and was stored at 4°C. Plasma was then used for the determination of digoxin, creatinine, total bilirubin, AST, ALT, GGT and albumin concentrations.
Laboratory Methods
Digoxin Assay. The Abbott Diagnostics TDx fluorescence polarisation immunoassay kit for digoxin was used with an Abbott TDx analyser to estimate DLIS in patients not receiving digoxin. 16 All assays were performed according to the manufacturer's protocol. The digoxin assay was linear from 0.05 to 6.4 nmol/l digoxin/litre plasma, and all results less than 0.05 nmol/l were considered to equal zero for both digoxin and DLIS. The concentration of plasma DLIS was estimated using a digoxin assay, as no DLIS 'standard' is available. DLIS results have been expressed as nmol/l against a digoxin standard.
Between-run precision was determined by measuring the digoxin concentration in plasma from patients receiving digoxin. A specimen with a mean digoxin concentration of 0.21 nmol/l and standard deviation (SD) of 0.046 nmol/l had a coefficient of variation (CV) of 22%. At a digoxin concentration of 1.15 nmol/l (SD 0.115 nmol/l), the CV was 10%. The between-run precision for DLIS was determined on plasma from an ICV patient with fulminant hepatic failure who was not receiving digoxin. The mean plasma DLIS was 0.69 nmol/l (SD 0.095 nmol/l) and the CV was 13.8%. Although the coefficients of variation are high at low digoxin concentrations, the small standard deviations indicate that low digoxin and DLIS concentrations can be readily distinguished from negative results and subjected to statistical analysis.
Other assays. Analyses of plasma electrolytes, creatinine, urea, albumin and liver function tests were performed using the Parallel multichannel biochemical analyser (American Monitor, Indianapolis). Urine sodium and creatinine were assayed using an IL 508 discrete analyser (Instrument Laboratories, Lexington, Ma.
). An enzymelinked spectrofluorimetric assay (Nyegaard & Co., Norway) was used for analysis of bile salts on an IL Multistat centrifugal analyser (Instrument Laboratories, Lexington, Ma.). Standard 100 Ilmolar solutions of individual bile salts in pooled human plasma were tested for digoxin-like immunoreactivity using the same TDx assay. The two-stage prothrombin determination was performed and expressed as the prothrombin index. APTT was measured using a standard tehnique of measuring the clotting time of recalcified citrated plasma. Statistical analyses. The unpaired Student's t test was used for statistical comparison between intensive care patients and control group subjects. Paired Student's t test and one-way analysis of variance were used to assess statistical differences between serial measurements of DLIS in ICU patients. Analyses that did not have Gaussian distributions (such as ICU patient subgroups) were analysed using non-parametric statistical analysis on the SPSS package. I? Correlations between plasma DLIS concentration and the other measured parameters were assessed by univariate and multiple regression analysis. RESULTS The sex ratio of the control group (64 male; 36 female) did not differ significantly from the ICU patients (63 male; 37 female). However, the age in years for the ICU patients (mean 49.3; SD 19.1; range 15-88) was significantly higher (P < 0.05) than that of the control group (mean 36.8; SD 13.3; range 19-65). In the ICU patients the plasma concentrations of bilirubin, creatinine, AST and AL T were significantly higher than those of the control group. The plasma albumin concentration was significantly lower.
As shown in Table 1 , the median plasma DLIS of the control subjects was less than the limit of detection of the assay (range 0 to 0.22). The median plasma DLIS was significantly higher (P<O.OOOI) in the ICU patients (median 0.17 nmol/l; range 0 to 1.69). As shown in Figure 1 , thirty ICU patients had plasma DLIS concentrations greater than or equal to 0.22 nmol/I. Two of these patients had a plasma DLIS concentration within the commonly accepted therapeutic range for digoxin (1.0-2.6 nmol/l). Table 2A shows the univariate correlation of DLIS with other parameters measured in ICU patients. A significant correlation was found between DLIS and bile salts, bilirubin, prothrombin index, urea, urinary sodium, urinary sodium/plasma sodium, APTT, plasma osmolality, ALP, protein and platelets. However, multiple regression analysis carried out on the 77 patients for whom full data was available (Table 2B) showed many of these variables were not independently related to DLIS. In these 77 patients, DLIS was most strongly correlated with bile salts. The addition of bilirubin resulted in an increase in the cumulative multiple regression of 0.016. Plasma potassium gave a further increase 0.015, urea 0.012 and creatinine 0.006. All other analyses gave an increase of~0.005.1t is of interest that liver enzymes such as AST, ALT or GGT gave only trivial increases in the cumulative correlation (0.004, 0.004 and 0.001 respectively), as did age (0.004) and admission APACHE score (0.001) which were also not related to DLIS independently of other variables.
Comparisons of DLIS concentrations in ICU patients with various forms of organ dysfunction are shown in Table 1 and Figure 1 .
Forty-two patients had normal renal and hepatic function and were admitted for management of respiratory failure or for postoperative monitoring. In this group the median plasma DLIS concentration was 0.15 nmol/l (range 0-0.36). Four patients met the criteria for renal dysfunction but had normal liver function. The median plasma DLIS concentration in this group was 0.05 nmol/l (range 0-0.34).
Thirty-eight patients fulfilled the criteria for liver dysfunction but had normal renal function. The median plasma DLIS concentration in this group was 0.17 nmol/l (range 0-0.77). Sixteen patients met the in a commercial digoxin assay. In 30% of the ICU patients the DLIS value was greater than or equal to the highest value found in the control group (0.22 nmolll). In ICU patients, no significant difference was found between serial plasma DLIS concentration determinations made over two consecutive days (n = 18) or three consecutive days (n = 7).
The 'apparent' digoxin concentration ofthe 100 J..Lmolar solutions of individual bile salts in pooled human plasma are shown Table 3 .
DISCUSSION
Of one hundred consecutive Intensive Care Unit patients, who had never received digoxin therapy, 80% had a substance or substances in their plasma which showed immunoreactivity The Abbott fluorescence polarisation immunoassay kit used in this study was chosen because data from quality assurance programmes from the American Association of Clinical Chemists and the Royal College of Pathologists of Australasial Australian Association of Clinical Biochemists indicate that it is the most commonly used method for routine analysis of digoxin in both the United States of America and Australia. This kit was originally shown to exhibit a relatively low degree of interference and crossreactivity when compared with other immunoassay from plasma proteins. 20 The crossreactivity may also vary with different batches of antisera. 21 DLIS has been found in the plasma of patients with chronic liver disease 6 • 22 and fulminant hepatic failureY The results of this study support an association of DLIS with liver dysfunction, and further suggest a strong association between DLIS and plasma concentrations of total bilirubin in critically ill patients. Plasma DLIS concentration has previously been shown to be related to plasma bilirubin concentration in seven patients with liver dysfunction 24 and in twenty-one patients receiving spironolactone. 25 In this study a strong association was also shown between the presence of DLIS and the plasma concentration of total bile salts. This association has been observed in other studies. 24 ,26.27 Bile salts are closely related structurally to digitalis and have been shown to both inhibit Na+-K+ ATPase and to displace eH)-ouabain from the enzyme. 27 Consequently, bile salts may be a possible source of crossreactivity in the digoxin assay. The degree of crossreactivity was unable to be assessed in this study because plasma concentrations of individual bile salts were not determined. The apparent digoxin concentration of 100 /J.molar solution of cholate was 0.64 nmolll, whereas chenodeoxycholate did not show crossreactivity in the TDx digoxin assay. The relative contributions of· cholate, chenodeoxycholate and the secondary bile salts to total bile salt concentration in fulminant hepatic failure, cholestasis of sepsis and other forms ofliver dysfunction in critical illness are uknown. The data therefore do not exlude the possibility that bile salts may be the sole source of DLIS in this study, although it has been suggested that the degree of crossreactivity is less than 10%?
Although interference from spironolactone and prednisone was specifically excluded in this study, there remains the possibility that naturally occurring steroid substances such as cortisol and progesterone may be responsible for some crossreactivity. These substances have been implicated as nonspecific interfering substances in digoxin assays. 28 The study found no evidence to support the previously reported association between DLIS and renal dysfunction. 29 ,3o Only four patients met the criteria for renal dysfunction with normal hepatic function. However, in this group the plasma DLIS concentrations were not different from those of the control subjects and were lower than plasma DLIS concentrations in patients with liver dysfunction and those with coexisting renal and hepatic dysfunction. Furthermore, no correlation was demonstrated between plasma DLIS concentration and plasma creatinine concentration.
Relatively high DLIS concentrations in patients with co-existing renal and hepatic dysfunction have been observed previously. 24, 26 No mechanism has been advanced for this finding. DLIS has been found in urine of normal human subjects. 31 It is possible that 'production' of DLIS is increased with hepatic dysfunction and excretion is decreased in patients with renal impairment, resulting in increased plasma concentrations.
No correlation was demonstrated between plasma DLIS concentration and APACHE score. This data suggest that the presence and degree of liver dysfunction is a better indicator for the presence of DLIS than the severity of illness.
No difference was demonstrated between serial measurements of plasma DLIS concentration in the same patients over two or three consecutive days. This is in keeping with the strong associations demonstrated between DLIS concentration and plasma concentrations of bilirubin and bile salts.
It has been suggested that the presence of DLIS in plasma is related to abnormalities of protein binding and that carrier proteins may play an important role in its transport. 32 Plasma albumin concentration is known to fall in critical illness due to transcapillary escape. 33 However, in this study no relationship was demonstrated between plasma DLIS concentration and plasma albumin concentration, and therefore the findings do not suggest that changes in plasma albumin concentration are primarily responsible for the presence of DLIS in the ICU patients.
The plasma of critically ill patients that showed digoxin-like immunoreactivity were not tested for the ability to inhibit Na+ -K+ ATPase (i.e. digoxin-like activity). However, a relationship between Na+ -K+ ATPase inhibitory activity and crossreactivity with digoxin antisera has been demonstrated in a factor isolated from human urine, 8 the plasma of pregnant women 34 and neonates 35 supporting the hypothesis of the existence of an endogenous digoxin-like substance or substances. CONCLUSION This study shows that the majority of critically-ill patients not treated with digoxin are likely to exhibit measurable and sometimes high concentrations of DLIS as estimated by an immunoassay kit frequently used for measurement of plasma digoxin. The association between DLIS and hepatic dysfunction is strong and this finding has been supported by other studies. 23 ,27 Care should therefore be taken in interpreting plasma digoxin measurements in ICU patients treated with digitalis, and particularly in those patients with liver dysfunction where the measured plasma digoxin concentration may be falsely elevated to a clinically significant extent.
